Organon Shareholder Approval Achieved for Sun Pharma's Proposed Acquisition
Sun Pharmaceutical Industries Limited has announced that shareholders of Organon & Co. have approved the proposals related to the previously announced merger transaction. This approval marks a significant milestone toward the completion of the proposed acquisition.The shareholder consent confirms that Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., which operates as an indirect wholly owned subsidiary of Sun Pharma. The successful shareholder approval keeps the acquisition process moving forward, though the transaction remains subject to customary closing conditions and applicable regulatory approvals. For further details regarding this proposed transaction, reference should be made to Sun Pharma's announcement dated April 27, 2026.
Sun Pharmaceutical Industries Limited is described as a leading global pharmaceutical company, having a presence across Innovative Medicines, Generics, and Consumer Healthcare products. It stands as the largest pharmaceutical company in India and is a prominent generic leader in the US and Global Emerging Markets.
The company's high growth Global Innovative Medicines portfolio spans dermatology, ophthalmology, and onco-dermatology, accounting for about 22% of its sales. Sun Pharma maintains vertically integrated operations, delivering high-quality medicines that are trusted by consumers and physicians in over 100 countries. Its manufacturing facilities are distributed across five continents, supported by a multi cultural workforce drawn from more than 50 nations.
SUNPHARMA Stock Price Movement
Sun Pharmaceutical Industries Limited surged on Thursday, climbing 0.41% and closing at ₹1954, as the stock continued its impressive trajectory toward its 52-week high. The equity gained ₹8.00 in trading, settling after charting a session range between ₹1926.8 and ₹1958.5 on significant volume of 2.06 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.